INNO-GENE SA ZY -10 (WQ3) - Total Assets
Based on the latest financial reports, INNO-GENE SA ZY -10 (WQ3) holds total assets worth €25.00 Million EUR (≈ $29.23 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See WQ3 net asset value for net asset value and shareholders' equity analysis.
INNO-GENE SA ZY -10 - Total Assets Trend (2021–2024)
This chart illustrates how INNO-GENE SA ZY -10's total assets have evolved over time, based on quarterly financial data.
INNO-GENE SA ZY -10 - Asset Composition Analysis
Current Asset Composition (December 2024)
INNO-GENE SA ZY -10's total assets of €25.00 Million consist of 32.9% current assets and 67.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 1.1% |
| Accounts Receivable | €5.10 Million | 20.8% |
| Inventory | €21.55K | 0.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €13.48 Million | 55.0% |
| Goodwill | €1.99 Million | 8.1% |
Asset Composition Trend (2021–2024)
This chart illustrates how INNO-GENE SA ZY -10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see INNO-GENE SA ZY -10 market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INNO-GENE SA ZY -10's current assets represent 32.9% of total assets in 2024, a decrease from 91.5% in 2021.
- Cash Position: Cash and equivalents constituted 1.1% of total assets in 2024, down from 29.2% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 62.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 55.0% of total assets.
INNO-GENE SA ZY -10 Competitors by Total Assets
Key competitors of INNO-GENE SA ZY -10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Givaudan SA
F:GIN1
|
Germany | €11.86 Billion |
|
EVONIK INDUST.(U.ARD)2
F:EVKA
|
Germany | €17.98 Billion |
|
Huaibei Mining Holdings Co Ltd
SHG:600985
|
China | CN¥89.26 Billion |
|
Shandong Dongyue Organosilicon Mat
SHE:300821
|
China | CN¥6.07 Billion |
|
Fujian Kuncai Material Tech
SHG:603826
|
China | CN¥4.98 Billion |
|
Dalian Bio-Chem Co Ltd
SHG:603360
|
China | CN¥3.99 Billion |
|
Aarti Industries Limited
NSE:AARTIIND
|
India | Rs132.99 Billion |
|
Shenzhen Cotran New Material Co Ltd Class A
SHE:300731
|
China | CN¥1.34 Billion |
INNO-GENE SA ZY -10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.17 | 1.20 | 1.20 |
| Quick Ratio | 1.17 | 1.19 | 1.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.21 Million | €499.00K | €499.00K |
INNO-GENE SA ZY -10 - Advanced Valuation Insights
This section examines the relationship between INNO-GENE SA ZY -10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.07 |
| Latest Market Cap to Assets Ratio | 0.61 |
| Asset Growth Rate (YoY) | 338.2% |
| Total Assets | €24.52 Million |
| Market Capitalization | $14.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values INNO-GENE SA ZY -10's assets below their book value (0.61x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: INNO-GENE SA ZY -10's assets grew by 338.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for INNO-GENE SA ZY -10 (2021–2024)
The table below shows the annual total assets of INNO-GENE SA ZY -10 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €24.52 Million ≈ $28.67 Million |
+338.20% |
| 2023-12-31 | €5.60 Million ≈ $6.54 Million |
-45.51% |
| 2022-12-31 | €10.27 Million ≈ $12.01 Million |
-23.63% |
| 2021-12-31 | €13.45 Million ≈ $15.72 Million |
-- |
About INNO-GENE SA ZY -10
HyEnergy S.A. provides genetic diagnostic solutions in Poland. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of solid tumors. In addition, it provides DNA analysis and genetic diseases diagnostic service based on NGS technology. HyEnergy S.A. was formerly known as Inno-Gene S.A. and changed its name to HyEnergy S.A. in October 2024. … Read more